News

Explore Latest News .

Find all the latest news on Paul Peter Tak, as well as a comprehensive list of his past interviews and features. Paul Peter’s work in immunology and the pharmaceutical industry has led him to be featured in both business and medicine specific publications.

During his time at GlaxoSmithKline, Paul Peter gave a number of interviews and briefs, including one with the Biochemical Society in 2017. In this insightful interview, Paul Peter outlined what the GSK Immunology Network was and its impact on this important area of research.

In December 2020, Paul Peter Tak spoke with Eleanor Malone, from Scrip, about the work Candel Therapeutics was undertaking in the field of cancer immunotherapy and the companies ambitious future. Paul Peter has also had more broad discussions around his career and what inspires him, such as his interview with Stephanie Sutton for The Medicine Maker, in 2020.   

CANDEL THERAPEUTICS APPOINTS PHARMA VETERAN AND IMMUNOLOGIST PAUL-PETER TAK, M.D., PH.D., AS CHIEF EXECUTIVE OFFICER; EXPANDS LEADERSHIP TEAM WITH CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND CHIEF REGULATORY OFFICER APPOINTMENTS

– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response– Phase 3 prostate cancer program enrolling patients, clinica…

Pioneering Gut Science, Kintai Therapeutics Is Bringing a New Small Molecule Modality to Fruition

What if the gut, widely regarded as the body’s second brain, could offer a much more impactful means to effect broad systemic pharmacological actions of orally administered drugs based on the conflu…

Ten Pillars of Success for Building a Biotech Company (or any Innovative Organization)

First year reflections: Ten Pillars of Success for Building a Biotech Company View Article: https://www.linkedin.com/pulse/ten-pillars-success-building-biotech-company-any-innovative-tak/

Biocentury

Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets

GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket

GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. C…

Candel Aims High In Next Stage Of Cancer Immunotherapy Mission

Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023. View Article:…
Paul Peter Tak

© Paul Peter Tak.
All rights reserved.